Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Imunopharm Technology logo — Make the incurable curable

Imunopharm Technology

Make the incurable curable

Founded 2015 China Beijing, China 19 employees Series Unknown Total: $262.50M Biotechnology, Medical Devices +1

General Information

Company Name Imunopharm Technology
Founded Year 2015
Location China Beijing, China +1
Employees 19
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Series Unknown
Social

Get notified when Imunopharm Technology moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Imunopharm Technology

Immunochina, founded in 2015 in Beijing, is a clinical-stage biopharmaceutical company with the slogan "Make the incurable curable". The company is dedicated to developing innovative cell and gene therapies to combat serious diseases such as cancer and autoimmune disorders. It boasts an integrated autonomous platform for research and industrialization in the biotechnology and pharmaceutical industries. Immunochina's pipeline includes treatments for hematologic malignancies like lymphoma, leukemia, multiple myeloma, and solid tumors such as liver cancer and colorectal cancer. The company has presented clinical data of its CAR-T products at renowned international conferences including ASCO, ASH, IMS, and ESMO. Particularly noteworthy is its in-house CAR-T therapy product, IM96, which has shown groundbreaking efficacy and safety data in early clinical trials targeting GUCY2C for the treatment of late-stage metastatic colorectal cancer. The company has successfully completed 9 rounds of strategic financing and secured the CAR-T drug production license with 5 China INDs. The most recent injection of funds came from China Taiping Insurance in a Venture Round investment on 08 May 2023. Immunochina has solidified its position as a cornerstone in CAR-T therapy in China, making significant strides in the development of potential FIC therapies for late-stage CRC.

Taxonomy: gene cell therapy, cancer treatment, innovation platform, clinical trials, CAR-T technology, immune cell preparation, oncology research, biopharmaceutical, disruptive technology, medical technology development, high-tech enterprise, immune cell therapy, pharmaceutical manufacturing, medical research, scale-up plasmid preparation

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 1 •••• •••• 08 May 2023
Series D •••••• 2 •••• •••• 01 Nov 2022
Series D •••••• 4
Investor Investor
•••• •••• 		24 Nov 2021
Series C •••••• - 01 Dec 2020
Series C •••••• 1 •••• •••• 01 Oct 2020

View All 10 Funding Rounds

Imunopharm Technology Alternatives & Competitors

Imunopharm Technology vs
Innovative Cellular Therapeutics (ICT)
Innovative Cellular Therapeutics (ICT) United States

Our Patients are Depending on US

14 employees
Imunopharm Technology vs
Lyell Immunopharma
Lyell Immunopharma United States

At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.

Unknown
229 employees
Biotechnology
Imunopharm Technology vs
GeneMedicine
GeneMedicine Korea South

Biopharmaceutical company focusing on R&D and commercializing its oncolytic adenovirus platform for...

Series A
11 employees

FAQ About Imunopharm Technology

Make the incurable curable
Imunopharm Technology was founded in 2015.
Imunopharm Technology is headquartered in Beijing, China.
Imunopharm Technology operates in the following industries: Biotechnology, Medical Devices, Pharmaceutical.
Imunopharm Technology has approximately 19 employees.
Imunopharm Technology has completed 10 funding rounds, raising a total of $262.50M. The latest funding stage is Series Unknown.
Top alternatives and competitors to Imunopharm Technology include Innovative Cellular Therapeutics (ICT), Lyell Immunopharma, GeneMedicine, EV Therapeutics, Turnstone Biologics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Imunopharm Technology and Innovative Cellular Therapeutics (ICT) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Imunopharm Technology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy